Aug 20, 06:31 PM

FTC Supports FDA Proposal for Easier Biosimilar Market Entry

The Federal Trade Commission (FTC) has expressed support for a proposed guidance by the U.S. Food and Drug Administration (FDA) aimed at facilitating the market entry of biosimilar drugs. This proposal is designed to make it easier for drugmakers to demonstrate that biosimilar medicines are safe and effective substitutes for more expensive brand-name drugs. Biosimilars offer patients access to life-saving medications at more affordable prices, potentially impacting the pharmaceutical market significantly. The FTC's backing highlights the economic considerations and antitrust implications of biosimilar market entry, which are comparable to those of generic drugs. The proposal could streamline the approval process, enhancing competition and reducing healthcare costs.

#Federal Trade Commission #FTC #FDA

Written with ChatGPT (GPT-4o).

Sources

Law360@Law360
2 years ago
The Federal Trade Commission is backing a proposal that would make it easier for drugmakers to show biosimilar medicines are safe substitutes for their more expensive counterparts. https://t.co/7CscWMT2Rx https://t.co/ygeuPiIEyc
Lina Khan@linakhanFTC
2 years ago
1. Biosimilar drugs can give patients access to life-saving medications at more affordable prices than brand-name drugs. @FTC submitted a comment in support of a @US_FDA proposal that could make it easier for biosimilar drugs to get to market. https://t.co/1rZPi0fiO3
STAT@statnews
2 years ago
Opinion: The FDA and the EMA need to agree on an aligned regulatory approach to the development of complex generics. https://t.co/MvWleF5zE4

Additional media

Image #1 for story ftc-supports-fda-proposal-easier-biosimilar-market-entry

FTC Supports FDA Proposal for Easier Biosimilar Market Entry

Sources

Additional media

Similar Stories